VJOncology is committed to improving our service to you

ASCO 2020 | Atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer

VJOncology is committed to improving our service to you

Michael Morris

Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses results from a phase Ib study evaluating the safety and tolerability of atezolizumab with radium-223 in patients with metastatic castrate-resistance prostate cancer who have progressed after treatment with an androgen pathway inhibitor (NCT02814669). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter